Article Sidebar

Submitted
Feb 5, 2020
Published
Apr 28, 2020
Download
vol 6 no 1
Statistic
Read Counter : 987 Download : 2323

Downloads

Download data is not yet available.

Main Article Content

Abstract

Patients with hematological malignancy have a high risk of experiencing febrile neutropenia (FN). Acute Lymphoblastic Leukemia (ALL) became one of the most cases as a cause of FN. Chemotherapy can also cause of neutropenia in almost 90% of cases and can increase the risk of developing febrile neutropenia. The administration of irrational antibiotics can cause problems such as increased side effects and resistance. The purpose of this study is to determine the rationality of antibiotics in ALL with FN patients at  hospital X Surakarta. This study was an observational study with retrospectively. The research sample was met the inclusion criteria 31 patients with the purposive sampling method. Data were analyzed descriptively. An evaluation antibiotic of 31 patients ALL with FN was obtained the right indication 100% (31 patients), the right patient 100% (31 patients), the right medicine 83,87% (26 patients) and the right dose 51,61% (16 patients). The rationality of antibiotics was 51,61% (16 patients). 

Keywords

Febrile neutropenia Acute Lymphoblastic Leukemia Antibiotic

Article Details

References

  1. Aberg, J., Lacy, C., Amstrong, L., Goldman, M., & Lance, L. (2009). Drug Information Handbook, 17th Edition. Lexi-Comp for the American Pharmacists Association.
  2. Alwi, I., Salim, S., Hidayat, R., Kurniawan, J., & Tahapary, D.L. (2015). Demam Neutropenia, dalam Penatalaksanaan di Bidang Ilmu Penyakit Dalam: Panduan Praktis Klinik. Pusat Penerbitan Penyakit Dalam. Jakarta: 886–892.
  3. American Cancer Society. (2018). Cancer Statistics Center: Leukemia, American Cancer Society. Retrieved March 24, 2019, from: https://cancerstatisticscenter.cancer.org/#!/cancer-site/Leukemia
  4. Boxer, L., & Dale, D.C. (2002) Neutropenia: causes and consequences., Seminars in hematology, 39 (2), 75–81. Terdapat di: http://www.ncbi.nlm.nih.gov/pubmed/11957188 [Diakses pada Juni 19, 2019].
  5. BPOM RI. (2017). Informatorium Obat Nasional Indonesia (IONI). Badan Pengawas Obat dan Makanan Republik Indonesia, Jakarta
  6. Budiana, I.N.G., & Febiani, M. (2017). Febrile Neutropenia pada Pasien Pasca-Kemoterapi, Indonesian Journal of Cancer. 11 (2): 77–82.
  7. Freifeld, A.G., Bow, E.J., Sepkowitz, K.A., Boeckh, M.J., Ito, J.I., Mullen, C.A., Raad, I.I., Rolston, K. V., Young, J.A.H., & Wingard, J.R. (2011). Executive summary: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 52 (4): 427–431.
  8. Hadi, U., Duerink, D.O., Lestari, E.S., Nagelkerke, N.J., Keuter, M., Huis in't veld, D., et al. (2008). Audit of Antibiotic Prescribing in Two Governmental Teaching Hospitals in Indonesia. Clinical Microbiology and Infection. 14: 698-707
  9. Hamid, S., Widjajanto, P.H., & Laksono, I.S. (2013). Evaluasi sensitivitas antibiotik dengan demam neutropenia. Sari Pediatri. 15 (4): 220–24.
  10. Hapsari, M., Tamam, M., & Satrio, P. (2016). Faktor Risiko Terjadinya Demam Neutropenia pada Anak Leukemia Limfoblastik Akut. Sari Pediatri. 15 (1): 39.
  11. Hompedin. (2006). Panduan Tatalaksana febril Neutropeni/ Demam Neutropeni pada Pasien Kanker. Balai penerbit FKUI, Jakarta
  12. Ifora. (2015). Kajian Rasionalitas Penggunaan Antibiotik pada Penderita Leukemia Limfoblastik Akut (LLA) dengan Demam Neutropenia di Irna Anak RSUP dr. M. Djamil Padang. Thesis. Pascasarjana, Universitas Andalas, Padang.
  13. Kementerian Kesehatan RI. (2011a). Modul Penggunaan Obat Rasional. Kementerian Kesehatan RI, Jakarta.
  14. Kementerian Kesehatan RI. (2011b). Pedoman Pelayanan Kefarmasian Untuk Terapi Antibiotik. Kementerian Kesehatan RI, Jakarta
  15. Kementerian Kesehatan RI. (2011c). Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406 Tahun 2011. Jakarta
  16. Kementrian Kesehatan RI. (2015). Pusat Data dan Informasi - Kementerian Kesehatan Republik Indonesia. Jakarta.
  17. Klastersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Aapro, M., Herrstedt, J., & on behalf of the ESMO Guidelines Committee. (2016). Management of febrile neutropaenia: ESMO clinical practice guidelines. Annals of Oncology. 27: 111–118.
  18. Muliyani, Perwitasar,i D.A., Andalusia, R., & Aisyi, M. (2014). Evaluasi Penggunaan Antibiotik pada Pasien Pediatri Leukimia Limfoblastik Akut dengan Febrile Neutropenia Selama Pemberian Kemoterapi di Rumah Sakit Kanker Dharmais Jakarta. Media Farmasi. 11 (1)
  19. Nursyirwan, S.R., & Windiastuti, E. (2018). Kejadian Demam Neutropenia pada Anak dengan Keganasan. Sari Pediatri. 19 (4): 220.
  20. Pusat Data dan Informasi. (2015). Situasi Penyakit Kanker. Buletin Jendela Data dan Informasi Kesehatan. 1: 2–10.
  21. Ranuhardy, D., Kurnianda, J., Abdulmuthalib, A., Kar, A., Acang, N., Mediatry., Fadjari, H., Tobing, M., & Ashariati, A. (2006). Panduan Tatalaksana Febril Neutropeni/ Demam Neutropeni pada Pasien Kanker. Balai Penerbit Fakultas Kedokteran Universitas Indonesia. Jakarta.
  22. Refdanita, Maksum, R., Nurgani, A., & Endang, P. (2014). Faktor yang Mempengaruhi Ketidak Sesuaian Penggunaan Antibiotik dengan Uji Kepekaan di Ruang Intensif Rumah Sakit Fatmawati Jakarta Tahun 2001-2002. Makara Kesehatan. Vol. 8 (1): 21-26.
  23. Setiawan, M.D.P., & Suega, K. (2014). Gambaran Karakteristik Pasien Demam Neutropenia di RSUP Sanglah Periode Januari-Oktober 2014. Jurnal Medika. Fakultas Kedokteran, Universitas Udayana, Bali.
  24. Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simbadibrata, K M., & Setiati, S. (2010). Buku Ajar Ilmu Penyakit Dalam Edisi V Jilid II. Pusat Penerbitan Ilmu Penyakit Dalam, Jakarta..
  25. University of California San Francisco. (2019). Neutropenia: Conditions & Treatments, California. Terdapat di: https://www.ucsfbenioffchildrens.org/conditions/neutropenia/ [Diakses pada Juni 19, 2019].
  26. Utami, E.R. (2011). Antibiotik, Resistensi, dan Rasionalitas Terapi. El-Hayah. 1 (4): 191–198.
  27. Walkovich, K., & Boxer, L.A. (2013). How to Approach Neutropenia in Childhood. Pediatrics in Review. 34 (4): 173–184.
  28. World Health Organization. (2009). Medicines Use in Primary Care in Developing and Transitional Countries. World Health Organization. Geneva.